T207. METABOLIC ADVERSE EFFECTS OF OFF-LABEL USE OF SECOND-GENERATION ANTIPSYCHOTICS IN THE ADULT POPULATION: A SYSTEMATIC REVIEW AND META-ANALYSIS

BACKGROUND: Second generation antipsychotics (SGAs) are approved by the US Food and Drug Administration (FDA) for the treatment of schizophrenia, bipolar disorder and treatment refractory depression. Since the late 1990’s, prescription of antipsychotics has more than doubled and off-label use (i.e....

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Schizophr Bull
Egile Nagusiak: Bowden, Sylvie, Tran, Veronica, Asgariroozbehani, Roshanak, Brett McIntyre, William, Agarwal, Mahavir, Siskind, Dan, Hahn, Margaret
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2020
Gaiak:
Poster Session III
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7234501/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/schbul/sbaa029.767
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak